Skip to main content
SpringerLink
Log in

Risikofaktormanagement bei KHK

Was ist evidenzbasiert?

  • Schwerpunkt
  • CME
  • Published:
CardioVasc Aims and scope

Abstract

Durch eine gezielte Behandlung von Risikofaktoren kann bei Patienten mit KHK der weitere Krankheitsverlauf maßgeblich beeinflusst werden. Eine Reduktion von Krankenhauseinweisungen, Verbesserung der Lebensqualität und Verlängerung der Lebenserwartung durch sekundärprophylaktische Maßnahmen ist gut belegt. Neben einer optimalen medikamentösen Therapie ist hierfür eine oft drastische Veränderung des Lebensstils mit den Schwerpunkten einer konsequenten Nikotinabstinenz, einer gesunden Ernährung und regelmäßiger körperlicher Aktivität notwendig. Daten aus der Versorgungsforschung zeigen, dass diese Ziele nur unzulänglich erreicht werden. Die Umsetzung der bestehenden Behandlungsleitlinien sollte daher mit Nachdruck verfolgt werden. Forschungsbedarf besteht insbesondere hinsichtlich der prognostischen Bedeutung einer Betablockertherapie bei Patienten mit stabiler KHK und erhaltener LV-Funktion, der prognostischen Bedeutung einer gezielten Gewichtsreduktion bei KHK-Patienten mit Übergewicht und Adipositas, der Effektivität psychosozialer Interventionen bei unterschiedlichen Patientengruppen und deren Implementierung in die Routineversorgung sowie hinsichtlich der Optimierung von strukturierten Rehabilitationsprogrammen und der Verbesserung der Patientencompliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Beck EB, Walther C., Körner A., Erbs S. Cardiovascular Risk Reduction in Childhood - Evidence and Strategies. European Cardiology 2010;5(2):34–39.

    Google Scholar 

  2. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 September 11;364(9438):937–952.

    Article  PubMed  Google Scholar 

  3. (World Health Organization (WHO). The global burden of disease: 2004 update. 2008.

    Google Scholar 

  4. Perk J, de BG, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012 July;33(13):1635–1701.

    Article  PubMed  CAS  Google Scholar 

  5. Gohlke H, Albus C, Bönner G et al. Leitlinie Risikoadjustierte Prävention von Herz- und Kreislauferkrankungen. http://leitlinien dgk org/files/2007_Leitlinie_Risikoadjustierte_Praevention pdf 2007.

    Google Scholar 

  6. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung. Version 1.X. 2006. 2006.

  7. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). NationaleVersorgungleitlinie Chronische KHK - Langfassung, Modul Medikamentöse Therapie, 2. Auflage. Version 1.X, 2011. 2011.

  8. Smith SC, Jr., Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011 November 29;124(22):2458–2473.

    Article  PubMed  Google Scholar 

  9. Heitzer T, Meinertz T. [Prevention of coronary heart disease: smoking]. Kardiol 2005;94 Suppl 3:III/30–III/42.

    Google Scholar 

  10. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies. N Engl J Med 1999 March 25;340(12):920–926.

    Article  PubMed  CAS  Google Scholar 

  11. Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR, Jr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997 March 13;336(11):755–761.

    Article  PubMed  CAS  Google Scholar 

  12. Gellert C, Schottker B, Muller H, Holleczek B, Brenner H. Impact of smoking and quitting on cardiovascular outcomes and risk advancement periods among older adults. Eur J Epidemiol 2013 February 9.

    Google Scholar 

  13. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008;(2):CD000165.

    PubMed  Google Scholar 

  14. Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J 2005 April;149(4):565–572.

    Article  PubMed  Google Scholar 

  15. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010 January 19;121(2):221–229.

    Article  PubMed  CAS  Google Scholar 

  16. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 October 8;366(9493):1267–1278.

    Article  PubMed  CAS  Google Scholar 

  17. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006 August 1;48(3):438–445.

    Article  PubMed  CAS  Google Scholar 

  18. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) 2009 June;70(6):815–828.

    Article  CAS  Google Scholar 

  19. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013 February 26.

    Google Scholar 

  20. Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 November 29;367(22):2089–2099.

    Article  PubMed  CAS  Google Scholar 

  21. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 December 14;360(9349):1903–1913.

    Article  PubMed  Google Scholar 

  22. Bangalore S, Steg G, Deedwania P et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012 October 3;308(13):1340–1349.

    Article  PubMed  CAS  Google Scholar 

  23. Bao B, Ozasa N, Morimoto T et al. beta-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovasc Interv Ther 2013 April;28(2):139–147.

    Article  PubMed  CAS  Google Scholar 

  24. Ozasa N, Morimoto T, Bao B et al. beta-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 2012 November 2.

    Google Scholar 

  25. Dickinson HO, Mason JM, Nicolson DJ et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006 February;24(2):215–233.

    Article  PubMed  CAS  Google Scholar 

  26. Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006 June 20;144(12):884–893.

    Article  PubMed  Google Scholar 

  27. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001 February 12;161(3):397–405.

    Article  Google Scholar 

  28. Schondorf T, Lubben G, Karagiannis E, Erdmann E, Forst T, Pfutzner A. Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study. Diab Vasc Dis Res 2010 April;7(2):145–150.

    Article  PubMed  Google Scholar 

  29. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 January;28(1):88–136.

    PubMed  CAS  Google Scholar 

  30. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 February 7;346(6):393–403.

    Article  PubMed  CAS  Google Scholar 

  31. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;(3):CD002968.

    Google Scholar 

  32. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009 November;52(11):2288–2298.

    Article  PubMed  CAS  Google Scholar 

  33. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012 July 26;367(4):319–328.

    Article  PubMed  CAS  Google Scholar 

  34. Eilat-Adar S, Eldar M, Goldbourt U. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol 2005 February 15;161(4):352–358.

    Article  PubMed  Google Scholar 

  35. Sierra-Johnson J, Romero-Corral A, Somers VK et al. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil 2008 June;15(3):336–340.

    Article  PubMed  Google Scholar 

  36. Lavie CJ, De SA, Milani RV. Is there an obesity, overweight, or lean paradox in coronary heart disease? Getting to the 'fat' of the matter. Heart 2013 May;99(9):596–598.

    Article  PubMed  Google Scholar 

  37. Sattelmair J, Pertman J, Ding EL, Kohl HW, III, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 2011 August 16;124(7):789–795.

    Article  PubMed  Google Scholar 

  38. Schuler G. [Physical activity]. Z Kardiol 2005;94 Suppl 3:III/11–III/14.

    Google Scholar 

  39. Hambrecht R, Walther C, Mobius-Winkler S et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004 March 23;109(11):1371–1378.

    Article  PubMed  Google Scholar 

  40. Belardinelli R, Paolini I, Cianci G, Piva R, Georgiou D, Purcaro A. Exercise training intervention after coronary angioplasty: the ETICA trial. J Am Coll Cardiol 2001 June 1;37(7):1891–1900.

    Article  PubMed  CAS  Google Scholar 

  41. Taylor RS, Brown A, Ebrahim S et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004 May 15;116(10):682–692.

    Article  PubMed  Google Scholar 

  42. Heran BS, Chen JM, Ebrahim S et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2011;(7):CD001800.

    Google Scholar 

  43. European Heart Network. Diet, Physical Activity and Cardiovascular Disease in Europe. 2011.

    Google Scholar 

  44. Ladwig K-H, Lederbogen F, Albus C et al. Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie - Update 2013. Kardiologe 2013;7:7–27.

    Article  Google Scholar 

  45. Muller-Riemenschneider F, Damm K, Meinhard C et al. Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technol Assess 2009;5:Doc16.

    Google Scholar 

  46. Kotseva K, Wood D, de BG, de BD, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009 April;16(2):121–137.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universität Leipzig — Herzzentrum, Klinik für Innere Medizin / Kardiologie, Leipzig, Deutschland

    Ephraim B. Winzer & Gerhard C. Schuler

Authors
  1. Ephraim B. Winzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerhard C. Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Literatur im Internet unter cardiovasc.de

Erklärung zu Interessenkonflikten

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Die Autoren legen folgende potenziellen Interessenkonflikte offen: keine. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winzer, E.B., Schuler, G.C. Risikofaktormanagement bei KHK. CV 13, 34–42 (2013). https://doi.org/10.1007/s15027-013-0167-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-013-0167-y

Schlüsselwörter

Search

Navigation